Coming to Grips with A Multiple Myeloma Diagnosis
At the 2019 CURE® Educated Patient® Summit on Multiple Myeloma patient advocate and 10-year survivor Terry White had the chance to share advice on handling a cancer diagnosis.
Addressing Questions From Newly Diagnosed Patients with Multiple Myeloma
Naturally, newly diagnosed patients with multiple myeloma have a lot of questions for their physicians. Dr. Joshua Richter had the time to discuss some of them.
Real-World Data Shows Promise for Patients on CAR-T Therapy
Real-world data shows that CAR-T therapy can lower costs for patients with pre-existing comorbidities outside of the clinical setting.
Oral Paclitaxel Improves Response, Reduces Peripheral Neuropathy in Metastatic Breast Cancer
Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.
Men with Breast Cancer Must Attend Major Conferences to Advocate for Themselves
At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.
Circulating Tumor DNA After Neoadjuvant Chemo May Determine Risk of Recurrence in TNBC
Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.
Measuring Residual Cancer Burden Could Help Improve Predictions of Breast Cancer Outcomes
Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.
Understanding the Role of Immunoglobulins in Multiple Myeloma
At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.
MRD Measurement Shows Promise for Making Informed Treatment Decisions in Myeloma
At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.
Patients with Multiple Myeloma Give Themselves Hope Through Treatment
Dr. Cesar Rodriguez offers a message of hope and self-determination for patients with multiple myeloma.
Menopausal Hormone Therapy with Estrogen Alone Decreases Breast Cancer Incidence
Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.
Partial Breast Irradiation Is Effective in Preventing Recurrence in Patients with Early-Stage Breast Cancer
Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.
Awareness for Men With Breast Cancer is Starting to Take Hold at Major Conferences
This massive event for women with breast cancer just may be “man’s breast friend”.
Arimidex Extends Benefit of Breast Cancer Recurrence Prevention in Postmenopausal Women
Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.
Adding Immunotherapy to Chemo Before Surgery May Not Improve Response Rates in TNBC
Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.
Keytruda Plus Chemotherapy Before and After Surgery Improves Response in Certain Patients with Triple-Negative Breast Cancer
Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.
Adding S-1 to Endocrine Therapy Improves Survival in Japanese Patients with Breast Cancer
Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.
Addition of Perjeta to Standard Care Improves Survival in HER2-Positive Early Breast Cancer
Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.
Pretreated Patients with HER2-Positive Metastatic Breast Cancer See Benefit from Investigational Drug
The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.
Three-Drug Combination Improves Progression-Free Survival in Patients with Multiple Myeloma
Expanding a combination from two drugs to three may lengthen the time until disease progression for patients with relapsed or refractory multiple myeloma.
Investigational Oral Chemotherapy Boosts Survival in Older Patients with AML
Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.
Genomic Sequencing Could Individualize Diagnosis, Treatment of Myeloid Cancers
Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.
Immunotherapy Is Superior to Chemotherapy for Children and Young Adults with Relapsed B-Acute Lymphoblastic Leukemia
In a phase 3 clinical trial, Blincyto (blinatumomab), a type of immunotherapy, improved survival and showed fewer side effects in young patients.
Ibrutinib and Rituximab Improve Progression-Free Survival for Patients with CLL
Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.
Clinical Trial Data Highlights Stark Socioeconomic Disparities in Survival Rates Among Children with AML
New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.
African American Patients Unnecessarily Excluded From AML Clinical Trials
Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.
Mosunetuzumab Produces Complete Remissions in Patients with Non-Hodgkin Lymphoma
Some patients with non-Hodgkin lymphoma may soon have a treatment option that could offer complete remission, according to new data presented at the American Society of Hematology 2019 Annual Meeting.
CAR-T Cell Therapy That Targets Two Proteins May Help Patients with Multiple Myeloma
A dual-targeted chimeric antigen receptor-T cell therapy showed a more than 90% overall response rate in patients with relapsed or refractory disease.
Early Study Findings Lead to FDA Breakthrough Therapy Designation for CAR-T Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
JNJ-4528 showed deep responses and proved to be safe in patients with multiple myeloma, according to CARTITUDE-1 study findings.
Kidney Cancer: What Is New in the Second-Line Treatment Setting?
Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.
2 Clarke Drive Cranbury, NJ 08512